-
FDA sets May 2027 decision date on AMT-130 gene therapy for HD
4 min read
Latest News
-
October 2026: This Month in Huntington’s Disease Research
4 min read
From sticky thoughts and pigs that model HD to DNA repair and promising drug trial results, October brought fresh insights into HD. Here’s what you might have missed!
-
Turning down huntingtin: Alnylam’s brezosiran shows promising early result
6 min read
An experimental treatment for HD developed by Alnylam has shown long-lasting huntingtin lowering after just one dose, with encouraging early safety data. A pivotal trial is now planned for 2027 to figure out if this drug, brezosiran, can slow HD.
-
Blurred Lines: When Similar Symptoms Can Mean Different Things
7 min read
When someone with Huntington’s disease experiences new symptoms, is HD always the cause? Not necessarily. A new review explores catatonia, an uncommon condition that can cause changes that overlap with HD symptoms.
-
Picking MSH3’s Pocket: New Insights into CAG Repeat Expansion
8 min read
Scientists discovered a pocket on a protein called MSH3 that helps it grab DNA containing CAG repeats. By blocking this interaction, they slowed the growth of CAG repeats in cells, without removing the protein entirely.
-
What Pigs Revealed that Mice Missed in Huntington’s Disease
9 min read
A change in one gene can disrupt thousands of others in HD. A study in pigs suggests an explanation: expanded huntingtin interferes with chemical marks on DNA. The same effect wasn’t seen in mice, showing that the animal model matters.
-
Mending the fabric of your genes
6 min read
Cells constantly mend tears and rips in the fabric of your DNA, like a cherished pair of jeans. Sometimes this mending can add C-A-Gs by mistake. A group of scientists examined whether other kinds of rips in the genetic fabric may be occurring in HD.
-
Could rewiring the brain’s “brakes” improve movement in Huntington’s disease?
6 min read
Scientists discovered that a specific type of brain cell becomes unusually quiet in Huntington’s disease. By restoring the activity of these cells in mice, they were able to rebalance brain circuits and improve movement.
-
Your Voice Matters: Using Speech to Monitor Huntington’s Disease
9 min read
HD researchers developed an AI-powered tool that analyzes a short counting task. Its speech measures reflected clinical scores and HD-related changes over time, suggesting it could be used as a remote monitoring tool in future.
-
Can’t Get You Out of My Head: The Huntington’s Disease Symptom That’s More Than Just Repetition
5 min read
Getting “stuck” on a thought, action, or conversation can be a symptom of HD—not stubbornness. New research suggests perseveration may begin earlier than previously thought and highlights the value of caregiver perspectives.
-
AMT-130 at Four Years: Hopeful Signs, Complex Controls
12 min read
uniQure reports that after 4 years, people given high-dose AMT-130 continue to show signs of slower HD progression, providing hope for their recent regulatory submission. But the new analyses are nuanced. We unpack the hopeful, but complex results.
-
September 2026: This month in Huntington’s disease research
5 min read
September brought progress across the HD research landscape. From brain waves and visual thinking to DNA repeats, nutrition, inclusive care, new technologies, and encouraging SKY-0515 data, we round up a busy month in Huntington’s disease research.
HDBuzz Trial Tracker
FDA accepts BLA for Priority Review, with a target decision date of 1 May 2027.
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
